"
Team:SupBiotech-Paris/Concept
From 2009.igem.org
(Difference between revisions)
Enguerrand (Talk | contribs) |
Enguerrand (Talk | contribs) |
||
| Line 8: | Line 8: | ||
|+ Tableau | |+ Tableau | ||
|- | |- | ||
| - | ! scope=col | | + | ! scope=col | Type/Problématique |
! scope=col | Stabilité | ! scope=col | Stabilité | ||
! scope=col | Toxicité | ! scope=col | Toxicité | ||
| Line 16: | Line 16: | ||
! scope=col | Industrialisation | ! scope=col | Industrialisation | ||
|- | |- | ||
| - | | width=" | + | | width="100px" | |
Virus | Virus | ||
| width="34%" | | | width="34%" | | ||
Revision as of 12:40, 14 October 2009
Project
Introduction Current therapies Gene therapies DVS Concept Tissue Vector Cell Vector Therapeutic plasmid Conclusion Implementation Tissue targeting Antitumor action Treatment modeling Conclusion
Ressources
BioBricks Material & Method Bibliography
Ethics & Safety
| Type/Problématique | Stabilité | Toxicité | Ciblage | Passage des membranes | Résistance au Syst. Immun. | Industrialisation |
|---|---|---|---|---|---|---|
|
Virus |
Bonne |
Forte |
Cellulaire |
Très Bon |
Nulle |
Difficile |
|
Phage |
Bonne |
Faible |
Cellulaire |
Faible |
Nulle |
Facile |
|
Bactérie |
Bonne |
Faible/Forte |
Tissulaire |
Nulle |
Faible/Forte |
Facile |
|
Nanoparticule lipidique |
Faible |
Faible |
Cellulaire |
Moyen |
Faible |
Moyenne |
|
Bonne |
Moyenne |
Cellulaire |
Faible |
Faible |
Moyenne |
